We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

GE Healthcare

GE Healthcare provides medical imaging and information technologies, medical diagnostics, patient monitoring systems,... read more Featured Products: More products

Download Mobile App




GE Healthcare and Affibody Collaborate to Develop PET Imaging Tracers

By MedImaging International staff writers
Posted on 26 Sep 2019
Print article
GE Healthcare (Chicago, IL, USA) and Affibody AB (Solna, Sweden) have entered into a strategic collaboration to develop and commercialize Affibody-based PET imaging tracers, with initial focus on HER2 and PD-L1.

Affibody is a clinical stage biopharmaceutical company focused on developing innovative bi- and multi-specific next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody molecules and Albumod. Affibody operates a focused experimental medicine model and currently has three clinical stage programs. The first two are therapeutic programs that target psoriasis, and B-cell driven autoimmune diseases, respectively. The third program is a diagnostic imaging program that is directed primarily towards metastatic breast cancer.

The Affibody technology is uniquely suited for the development of PET imaging tracers and ABY-025, a HER2-detecting Affibody-based PET imaging tracer, is currently in clinical development. ABY-025 provides a novel non-invasive and cost-effective approach to diagnose global HER2-expression in metastatic breast cancer patients using PET imaging. Affibody is currently working together with academic institutions to explore the clinical utility of ABY-025 further. The PD-L1 binding Affibody molecule is being developed as a diagnostic tool to improve selection and monitoring of patients with immuno-oncology treatments. The collaboration with GE Healthcare will accelerate studies through to a stage of clinical proof of concept.

“The initiation of a strategic collaboration with GE Healthcare around PET imaging tracers reflects the commitment of Affibody to precision medicine and biomarker guided patient treatment. It also underlines the competitiveness of our technology and the value of the clinical data that has been generated with Affibody-based imaging agents,” said David Bejker, CEO of Affibody. “We believe that our collaboration with GE Healthcare to develop and commercialize these imaging agents will make a significant contribution to enhance the treatment of cancer patients globally.”

“We recognize that PET imaging plays a vital role in the development and use of cancer immunotherapies as it is a non-invasive way to measure patient response before, during and after treatment,” said Sanka Thiru, Head of Molecular Imaging Oncology, in GE Healthcare’s Pharmaceutical Diagnostics business. “We are partnering with companies like Affibody to build a portfolio of molecular imaging agents for oncology, focusing on those disease biomarkers that will help accelerate the development of the next generation of cancer treatments.”

Gold Member
Solid State Kv/Dose Multi-Sensor
AGMS-DM+
MRI System
uMR 588
New
Color Doppler Ultrasound System
DRE Crystal 4PX
Ultrasound System
P25 Elite

Print article

Channels

Ultrasound

view channel
Image: Structure of the proposed transparent ultrasound transducer and its optical transmittance (Photo courtesy of POSTECH)

Ultrasensitive Broadband Transparent Ultrasound Transducer Enhances Medical Diagnosis

The ultrasound-photoacoustic dual-modal imaging system combines molecular imaging contrast with ultrasound imaging. It can display molecular and structural details inside the body in real time without... Read more

Nuclear Medicine

view channel
Image: PET/CT of a 60-year-old male patient with clinical suspicion of lung cancer (Photo courtesy of EJNMMI Physics)

Early 30-Minute Dynamic FDG-PET Acquisition Could Halve Lung Scan Times

F-18 FDG-PET scans are a way to look inside the body using a special dye, and these scans can be either static or dynamic. Static scans happen 60 minutes after the dye is administered into the body, showing... Read more

Imaging IT

view channel
Image: The new Medical Imaging Suite makes healthcare imaging data more accessible, interoperable and useful (Photo courtesy of Google Cloud)

New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible

Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.